SUCLG2 Antibody / Succinate-CoA ligase GDP-forming subunit beta, 100ug

SUCLG2 antibody targets Succinate-CoA ligase GDP-forming subunit beta (SUCLG2), a mitochondrial enzyme subunit that functions in the tricarboxylic acid cycle and cellular energy metabolism. SUCLG2 forms part of the succinate-CoA ligase complex, also known as succinyl-CoA synthetase, which catalyzes the reversible conversion of succinyl-CoA to succinate with the concomitant generation of GTP from GDP. This reaction represents a key step in substrate-level phosphorylation within the mitochondrial matrix, linking central carbon metabolism to cellular nucleotide balance. SUCLG2 localizes to mitochondria, consistent with its role in oxidative metabolism and energy production.<br><br>Functionally, SUCLG2 pairs with the alpha subunit of succinate-CoA ligase to form the GDP-specific isoform of the enzyme, distinguishing it from the ADP-forming variant that contains a different beta subunit. This GDP-forming activity is particularly important in tissues with high reliance on mitochondrial GTP production, such as liver, brain, and other metabolically active organs. By contributing to the tricarboxylic acid cycle, SUCLG2 supports efficient flux of carbon intermediates and integration of energy metabolism with biosynthetic and signaling pathways. An SUCLG2 antibody supports studies examining mitochondrial metabolism and energy regulation.<br><br>SUCLG2 plays a broader role in maintaining mitochondrial function beyond its enzymatic activity. Proper operation of the succinate-CoA ligase complex influences levels of succinate, a metabolite that also functions as a signaling molecule capable of modulating hypoxia-related pathways and epigenetic regulation. Alterations in SUCLG2 expression or activity can therefore impact both metabolic output and signaling networks linked to mitochondrial state. These features make SUCLG2 a relevant target for studies of metabolic adaptation and mitochondrial regulation.<br><br>From a biological and disease-relevance perspective, defects in succinate-CoA ligase components have been associated with inherited metabolic disorders and mitochondrial dysfunction. Although SUCLG2-associated disease phenotypes are less well characterized than those of other tricarboxylic acid cycle enzymes, impaired GDP-forming succinate-CoA ligase activity can contribute to altered energy homeostasis and tissue-specific metabolic vulnerability. SUCLG2 is also used in research contexts to help distinguish tissue-specific metabolic programs and mitochondrial enzyme composition.<br><br>At the molecular level, SUCLG2 is encoded by the SUCLG2 gene and produces a protein of approximately 433 amino acids that resides within the mitochondrial matrix. The protein contains conserved regions required for interaction with the alpha subunit and for binding nucleotide substrates during catalysis. Regulation of SUCLG2 expression is linked to metabolic state and mitochondrial biogenesis programs. An SUCLG2 antibody supports research applications focused on mitochondrial metabolism, tricarboxylic acid cycle function, and cellular energy balance, with NSJ Bioreagents providing reagents intended for research use.

Specifications